Trial reportBMJ (Clinical research ed.)2024
Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial.
Trial report in BMJ (Clinical research ed.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery: Follow-up Extension
The 10-Year Extended Follow-up of the Different Antiplatelet Strategies After Coronary Artery Bypass Grafting Trial
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- 'Aspirin versus ticagrelor for the management after coronary revascularization - a systematic review and meta‑analysis of randomised trials'.BMC cardiovascular disorders · 2026Pooled it
- Safety and efficacy of ticagrelor plus aspirin vs. aspirin monotherapy in patients undergoing coronary artery bypass grafting: A meta-analysis with trial sequential analysis.Journal of thrombosis and thrombolysis · 2026Pooled it
- Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial.BMJ (Clinical research ed.) · 2026Trial
- Indobufen Versus Aspirin After CABG for Unstable Angina in Patients Aged 70 Years and Older.Journal of cardiovascular development and disease · 2026Article
- Dual antiplatelet therapy with aspirin and ticagrelor vs aspirin alone in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2026Review
- Antithrombotic Therapy in Primary and Secondary Prevention of Coronary Artery Disease.Journal of clinical medicine · 2026Review
- Patient-centred anti-platelet therapy following coronary artery bypass graft surgery.Journal of thrombosis and thrombolysis · 2026Review
- Time- and risk-dependent effects of dual antiplatelet therapy targeting the P2Y12 receptor after CABG: A network meta-analysis of graft permeability and clinical outcomes.Journal of thrombosis and thrombolysis · 2026Review
- Article
- Myocardial Revascularization in 2025: A Clinical Perspective on the Evolution of Technologies, Strategic Decision-Making, and Future Horizons.Reviews in cardiovascular medicine · 2026Review
- Impact of Warfarin and Dual Antiplatelet Therapy on Graft Failure After Coronary Endarterectomy: A Retrospective Cohort Study.Cardiovascular drugs and therapy · 2026Article
- Determinants of graft patency after coronary artery bypass grafting.Frontiers in cardiovascular medicine · 2026Review
- Expert Review of the Strategies to Optimize Long-Term Outcomes After Coronary Artery Bypass Grafting.Reviews in cardiovascular medicine · 2025Review
- Effect of P2Y12 Inhibitors on Major Adverse Cardiovascular Events After Coronary Artery Bypass Graft Surgery: A Population-Based Cohort Study.Pharmacotherapy · 2025Article
- New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Optimal treatment for nonsevere coronary artery disease in valve surgeries: Concurrent coronary artery bypass grafting or postoperative medical therapy?JTCVS open · 2025Article
- The impact of clopidogrel combined with aspirin or aspirin alone on prognosis and adverse events in patients undergoing coronary artery bypass grafting in the first month after surgery.Frontiers in cardiovascular medicine · 2025Article
- Antithrombotic Therapy for Acute Coronary Syndrome.Journal of neuroendovascular therapy · 2025Review
- Research designs for cardiothoracic surgeons: part 1 - a primer for evidence-based practice.Indian journal of thoracic and cardiovascular surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effect of different antiplatelet strategies on clinical outcomes after coronary artery bypass grafting.
designFive year follow-up of randomised Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Grafting (DACAB) trial.
settingSix tertiary hospitals in China; enrolment between July 2014 and November 2015; completion of five year follow-up from August 2019 to June 2021.
participants500 patients aged 18-80 years (including 91 (18.2%) women) who had elective coronary artery bypass grafting surgery and completed the DACAB trial.
interventionsPatients were randomised 1:1:1 to ticagrelor 90 mg twice daily plus aspirin 100 mg once daily (dual antiplatelet therapy; n=168), ticagrelor monotherapy 90 mg twice daily (n=166), or aspirin monotherapy 100 mg once daily (n=166) for one year after surgery. After the first year, antiplatelet therapy was prescribed according to standard of care by treating physicians.
main outcome measuresThe primary outcome was major adverse cardiovascular events (a composite of all cause death, myocardial infarction, stroke, and coronary revascularisation), analysed using the intention-to-treat principle. Time-to-event analysis was used to compare the risk between treatment groups. Multiple post hoc sensitivity analyses examined the robustness of the findings.
resultsFollow-up at five years for major adverse cardiovascular events was completed for 477 (95.4%) of 500 patients; 148 patients had major adverse cardiovascular events, including 39 in the dual antiplatelet therapy group, 54 in the ticagrelor monotherapy group, and 55 in the aspirin monotherapy group. Risk of major adverse cardiovascular events at five years was significantly lower with dual antiplatelet therapy versus aspirin monotherapy (22.6%
conclusionsTreatment with ticagrelor dual antiplatelet therapy for one year after surgery reduced the risk of major adverse cardiovascular events at five years after coronary artery bypass grafting compared with aspirin monotherapy or ticagrelor monotherapy.
trial registrationNCT03987373ClinicalTrials.gov NCT03987373.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.